restriction vs dose adjustment
ELUCIREM: no renal adjustment does not mean unrestricted use
The same source states no renal dose adjustment and separately warns to avoid gadolinium in renal impairment unless diagnostic information is essential and unavailable through alternatives.
What to reconcileResolve whether contrast is appropriate before selecting a dose. Preserve the warning alongside the no-adjustment statement.
1 source identities and dates
GlobalRPh RX List - Gadopiclenol (Elucirem)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Intravenous ELUCIREM; selected renal precautions, not a complete imaging-selection protocol.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
institutional protocol difference
Gadolinium: existing-dialysis timing differs between dated sources
The 2021 ACR-NKF abstract regards dialysis alteration as generally unnecessary after its group II/III agents. UCSF seeks prompt hemodialysis, preferably within 24 hours, for existing dialysis patients. Both distinguish this from starting prophylactic dialysis.
What to reconcileReconcile the agent, date and local radiology/nephrology policy. Do not delay essential imaging or initiate dialysis automatically; no agent classification is inferred from a class name.
2 source identities and dates
ACR-NKF consensus: gadolinium and kidney disease (2021 abstract)ACR and National Kidney Foundation / author institutional repository | Source revision: 2021; Kidney Medicine 3(1):142-150.
2021 ACR-NKF consensus abstract about the agents classified as group II/III in that publication; not a current all-agent classification table.
Read this stored source UCSF gadolinium policy: dialysis schedulingUCSF Radiology | Source revision: Undated policy page; references ACR 2017 version 10.3.
UCSF institutional MRI contrast policy; the page references ACR Manual version 10.3 (2017).
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
indication and toxicity context
Gemcitabine: initial CKD guidance does not cancel a toxicity stop rule
eviQ supplies an initial indexed-eGFR approach for advanced pancreatic cancer. GEMZAR separately requires stopping for HUS or severe renal toxicity. These address different clinical states rather than permission to continue despite new injury.
What to reconcileEstablish baseline stability versus new drug-associated injury, indication and concomitant agents. Preserve the full toxicity monitoring and stop instructions.
2 source identities and dates
GlobalRPh RX List - GemzarGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
GEMZAR intravenous cytotoxic therapy; renal toxicity precautions distinct from stable-CKD dose selection.
Read this stored source eviQ 333: advanced pancreatic cancer gemcitabineeviQ / Cancer Institute NSW | Source revision: Current retrieved protocol; kidney recommendations reference ADDIKD.
Adult locally advanced/metastatic pancreatic cancer single-agent protocol; not all gemcitabine combinations.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
monitoring scope
EXXUA: a renal dose alone does not satisfy initiation safety checks
The reduced renal maximum does not remove ECG, electrolyte, hepatic or interaction restrictions.
What to reconcileApply the source-defined ECG/electrolyte prerequisites and complete interaction review before initiation or titration.
1 source identities and dates
GlobalRPh RX List - EXXUAGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
EXXUA extended-release tablets for adult major depressive disorder; renal dosing does not override QT, interaction or hepatic restrictions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v4.5.
label version and indication
BLUJEPA: moderate impairment is not always sufficient for eligibility
The newer label includes gonorrhea-specific combined exposure risks not covered by a simple uUTI renal cutoff. No adjustment within a renal band does not override indication-specific QTc avoidance conditions.
What to reconcileConfirm indication, weight, interacting medicines and hepatic function; do not invent a reduced gonorrhea regimen to bypass an avoidance condition.
2 source identities and dates
Gepotidacin tablets (Blujepa, adult renal comments) - selected U.S. label sectionsU.S. product labeling / DailyMed | Source revision: 2/2026
Adult BLUJEPA oral tablets. Uncomplicated urinary infection and gonorrhea regimens are not interchangeable.
Read this stored source BLUJEPA tablets: February 2026 renal and QTc restrictionsDailyMed / GlaxoSmithKline | Source revision: February 2026
BLUJEPA uUTI and uncomplicated urogenital gonorrhea; selected indication-specific renal and interaction restrictions.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
source scope and renal guidance
Before use: Glimepiride - AMARYL oral tablets
A low starting dose is not proof that advanced renal failure or dialysis is risk-free.
What to reconcileConfirm the exact product, indication, renal measure and full source before prescribing.
1 source identities and dates
GlobalRPh RX List - AMARYL oral tabletsGlobalRPh-hosted RX List | Source revision: 12/2016
Adults with type 2 diabetes; oral glimepiride.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.3.
source scope and renal guidance
Before use: Glipizide - extended-release tablets
The ER hypoglycemia warning names renal impairment in the 2.5 mg starting population. IR wording is qualitative and must remain separate.
What to reconcileConfirm ER formulation, meal intake, glucose trend and co-therapy; the starting dose is not a renal-stage maintenance algorithm.
1 source identities and dates
Glipizide - extended-release tabletsDailyMed / NLM exact product labeling | Source revision: 01/2023
Adults with type 2 diabetes; Aurobindo extended-release glipizide.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
source scope and renal guidance
Before use: Glipizide - immediate-release tablets
The IR label gives conservative initiation and maintenance advice; the newly retrieved ER label explicitly starts hypoglycemia-prone patients, including renal impairment, at 2.5 mg.
What to reconcileSelect immediate-release versus extended-release before applying the starting instruction; do not invent a CrCl-based schedule.
1 source identities and dates
Glipizide - immediate-release tabletsDailyMed / NLM exact product labeling | Source revision: Revision not established in selected retrieval
Adults with type 2 diabetes; Advagen immediate-release glipizide tablets.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v6.4.
monitoring and indication
VORAXAZE: rescue eligibility, leucovorin timing and assay artifact
Rescue is tied to delayed methotrexate elimination with kidney dysfunction. After glucarpidase, an immunoassay may remain misleading, and leucovorin timing matters.
What to reconcileFollow the complete rescue pathway and validated concentration method; do not infer a repeat dose from an interfering assay.
1 source identities and dates
GlobalRPh RX List - Glucarpidase (Voraxaze)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VORAXAZE rescue for toxic methotrexate exposure with delayed clearance due to renal dysfunction; not routine renal prophylaxis.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
formulation distinction
GLYNASE and MICRONASE: renal risk plus nonequivalent formulations
The micronized and nonmicronized products are not dose-for-dose bioequivalent. Both sources require conservative dosing with renal impairment and hypoglycemia surveillance.
What to reconcileRetitrate a formulation switch instead of carrying across the old milligram dose. Review alternatives and individual hypoglycemia risk.
1 source identities and dates
GlobalRPh RX List - Glynase PresTabGlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Micronized GLYNASE PresTab; not bioequivalent dose-for-dose to MICRONASE.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
formulation distinction
Glycopyrrolate: an IV study is not an oral prescription
The oral ODT label cites intravenous renal-transplant pharmacokinetics. GLYRX-PF and ROBINUL injection are separate products; CUVPOSA has pediatric oral-solution guidance.
What to reconcileMatch route, dosage form and population before using a source. No numerical adjustment is inferred from the IV study.
1 source identities and dates
GlobalRPh RX List - Glycopyrrolate (Dartisla ODT)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
DARTISLA ODT oral formulation; cited IV pharmacokinetics are not an IV administration instruction.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
pharmacokinetic scope
Systemic glycopyrronium findings do not establish a topical renal schedule
The topical renal pharmacokinetic study is missing. The source discusses systemic observations and anticholinergic risk, not a measured topical adjustment regimen.
What to reconcileKeep topical and systemic products separate. An unstudied population is not a no-adjustment determination; review urinary-retention symptoms and product-specific cautions.
1 source identities and dates
GlobalRPh RX List - QBREXZAGlobalRPh-hosted RX List | Source revision: October 2022
Glycopyrronium 2.4% cloth for axillary topical use; not systemic glycopyrrolate.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.5.
renal measure and formulation
GOCOVRI: MDRD method despite a creatinine-clearance heading
The label expressly uses MDRD and indexed units. The immediate-release amantadine record has different product-specific schedules; a numerically similar renal value is not proof of equivalence.
What to reconcileVerify renal method and formulation before selecting the nightly extended-release regimen. Do not transfer an immediate-release schedule or dialysis dose.
1 source identities and dates
GOCOVRI extended-release capsules: February 2026 labelDailyMed / Supernus Pharmaceuticals | Source revision: February 2026
GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
monitoring and measurement
VYONDYS 53: creatinine and urine-assay interpretation
Low muscle mass limits creatinine-based estimation, while excreted drug can interfere with a urine protein assay. Neither issue supplies an automatic renal dose.
What to reconcileUse the specified kidney markers, sampling timing and assay precautions. Persistent abnormalities require specialist assessment, not dismissal as artifact.
1 source identities and dates
GlobalRPh RX List - Golodirsen (Vyondys 53)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
formulation distinction
SUSTOL: depot formulation matters despite IV granisetron PK
SUSTOL has a longer minimum interval in moderate impairment and avoidance in severe impairment. The separate IV KYTRIL single-dose clearance observation cannot be applied to the polymer depot.
What to reconcileCheck route and release mechanism; read the local IV record only as a related, noninterchangeable product.
1 source identities and dates
GlobalRPh RX List - Granisetron ER (Sustol)GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
SUSTOL 10 mg subcutaneous extended-release product for chemotherapy-associated nausea/vomiting; not IV KYTRIL.
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.9.
product schedule difference
Dialysis vaccine dose counts and volumes are not interchangeable
RECOMBIVAX HB dialysis formulation and ENGERIX-B both use a high-dose adult approach, but their concentrations, injection volumes and series schedules differ. CDC directs readers to each product insert.
What to reconcileVerify actual vaccine, formulation, prior doses and anti-HBs follow-up. Do not convert one product's volume or three-dose schedule into the other product's regimen.
2 source identities and dates
GlobalRPh RX List - RECOMBIVAX HB dialysisGlobalRPh-hosted RX List | Source revision: April 2023
IM RECOMBIVAX HB 40 mcg/mL dialysis formulation; adults >=18 years
Read this stored source CDC hepatitis B vaccination - adult hemodialysisCDC | Source revision: Source revision date not established in selected retrieval.
Adult hepatitis B vaccination in hemodialysis; product-specific schedules remain separate
Read this stored source Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.